Susan Keefe - Feb 2, 2022 Form 4 Insider Report for GreenLight Biosciences Holdings, PBC (GRNA)

Role
CFO & Interim CAO
Signature
/s/ David Kennedy, Attorney-in-fact
Stock symbol
GRNA
Transactions as of
Feb 2, 2022
Transactions value $
$0
Form type
4
Date filed
2/4/2022, 07:01 PM
Next filing
Aug 8, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GRNA Stock Option (Right to Buy) Award +488K 488K Feb 2, 2022 Common Stock 488K $0.50 Direct F1, F2
transaction GRNA Stock Option (Right to Buy) Award +566K 566K Feb 2, 2022 Common Stock 566K $0.98 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 20% of the shares underlying the option vested or shall vest on June 3, 2020 and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting July 3, 2020.
F2 This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company.
F3 25% of the shares underlying the option vested or shall vest on December 1, 2021 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting January 1, 2022.